

CC-1065 Partial Structures: Enhancement of Noncovalent Affinity for DNA Minor Groove Binding through Introduction of Stabilizing Electrostatic Interactions

Dale L. Boger* and Subas M. Sakya

Department of Chemistry, Purdue University, West Lafayette, Indiana 47907

Received September 18, 1991

The preparation and DNA binding properties of ACDPI_n (4-7, *n* = 1-4) and TACDPI_n (8-10, *n* = 1-3) are detailed. Comparable to observations made with CDPI_n (*n* = 1-5), ACDPI₃ proved to be the optimal minor groove binding agent within the ACDPI_n series, and the agents exhibited a selectivity for AT- versus GC-rich DNA which is most pronounced with ACDPI₃. Similarly, TACDPI_n (*n* = 1-3) exhibited a substantial AT- versus GC-rich DNA binding selectivity (*n* = 3, $\Delta\Delta G^\circ = -2.7$ to -3.5 kcal). The direct comparison of CDPI_n with ACDPI_n illustrated that the introduction of a C-5 amino substituent onto the peripheral face of the agent reduces the DNA binding affinity presumably through introduction of destabilizing electrostatic interactions. In contrast, the comparison with TACDPI_n revealed that the introduction of a C-5 quaternary amine substantially enhanced the DNA binding affinity through introduction of stabilizing electrostatic interactions.

(+)-CC-1065 (1), an antitumor antibiotic isolated from *Streptomyces zelensis*,^{1,2} has been shown to possess exceptionally potent in vitro cytotoxic activity,³ efficacious in vivo antitumor activity,⁴ and broad-spectrum antimicrobial activity.¹ The antitumor activity of 1 has been related to its sequence-selective alkylation of DNA within high affinity minor groove sites that has been demonstrated to proceed by 3'-adenine N3 alkylation of the electrophilic cyclopropane present in the left-hand subunit (CPI) of the agent.^{5,6} The observation that (+)-*N*-acetyl-CPI exhibits a comparable albeit less intense (ca. 10000 \times) DNA alkylation within some segments of double-stranded DNA has led to the suggestion that the alkylation subunit of 1 plays the dominant role in determining the alkylation selectivity.⁵ This has been further interpreted to be due to a rate-determining, sequence-dependent autocatalytic activation of the alkylation reaction by a strategically located phosphate in the DNA backbone two base-pairs removed from the alkylation site.⁷ However, more recent studies have addressed an additional origin of the alkylation selectivity that may be related to the sequence-dependent conformational variability of duplex DNA.⁸

Complementary to these more recent studies, we have shown that simplified agents including CDPI₃ methyl ester exhibit a substantial preference for minor groove binding within AT-rich versus GC-rich DNA^{9,10} attributable to the preferential stabilization of the noncovalent complex within the narrower, sterically more accessible AT-rich minor groove.^{11,12} In these efforts, the profile of DNA alkylation by simple derivatives of the alkylation subunit proved to be readily distinguishable from that of (+)-CC-1065^{13,14} and an autocatalytic phosphate activation of the alkylation reaction was shown not to be uniquely responsible for the alkylation selectivity.¹⁴⁻¹⁶ In these studies, the electrophilic cyclopropane proved not to be obligatory to observation of the (+)-CC-1065 characteristic alkylation selectivity and the apparent noncovalent binding selectivity of the agents was shown to exhibit a pronounced effect. In the course of the continuing investigations,¹⁷⁻²⁰ we have examined the effects of the peripheral substituents on the noncovalent DNA minor groove binding affinity and selectivity of agents related to CC-1065.⁹

Herein, we report the results of a study of ACDPI_n (4-7, *n* = 1-4) which highlight an apparent destabilizing con-

tribution to the DNA binding affinity through introduction of a strong electronegative substituent onto the peripheral

(1) Chidester, C. G.; Krueger, W. C.; Mizesak, S. A.; Duchamp, D. J.; Martin, D. G. *J. Am. Chem. Soc.* 1981, 103, 7629. Hanka, L.; J.; Dietz, A.; Gerpheide, S. A.; Kuentzel, S. L.; Martin, D. G. *J. Antibiot.* 1978, 31, 1211. Martin, D. G.; Biles, C.; Gerpheide, S. A.; Hanka, L. J.; Krueger, W. C.; McGovern, J. P.; Mizesak, S. A.; Neil, G. L.; Stewart, J. C.; Visser, J. *J. Antibiot.* 1981, 34, 1119.

(2) Rachelmycin, isolated from *Streptomyces* strain C-329 has been shown to be identical to CC-1065: Nettleton, D. E.; Jr.; Bush, J. A.; Bradner, W. T. U.S. Patent 4,301,248; *Chem. Abstr.* 1982, 96, 33362e.

(3) Bhuyan, B. K.; Newell, K. A.; Crampton, S. L.; Von Hoff, D. D. *Cancer Res.* 1982, 42, 3532.

(4) Martin, D. G.; Chidester, C. G.; Duchamp, D. J.; Mizesak, S. A. *J. Antibiot.* 1980, 33, 902.

(5) Hurley, L. H.; Reynolds, V. L.; Swenson, D. H.; Petzold, G. L.; Scahill, T. A. *Science* 1984, 226, 843. Reynolds, V. L.; Molineux, I. J.; Kaplan, D. J.; Swenson, D. H.; Hurley, L. H. *Biochemistry* 1985, 24, 6228. Hurley, L. H.; Lee, C.-S.; McGovern, J. P.; Warpehoski, M. A.; Mitchell, M. A.; Kelly, R. C.; Aristoff, P. A. *Biochemistry* 1988, 27, 3886.

(6) For recent reviews see: Warpehoski, M. A.; Hurley, L. H. *Chem. Res. Toxicol.* 1988, 1, 315. Coleman, R. S.; Boger, D. L. In *Studies in Natural Products Chemistry*; Atta-ur-Rahman, Ed.; Elsevier: Amsterdam, 1989; Vol. 3, p 301. Rawal, V. H.; Jones, R. J.; Cava, M. P. *Heterocycles* 1987, 25, 701.

(7) Hurley, L. H.; Warpehoski, M. A.; Lee, C.-S.; McGovern, J. P.; Scahill, T. A.; Kelly, R. C.; Mitchell, M. A.; Wicnienski, N. A.; Gebhard, L.; Johnson, P. D.; Bradford, V. S. *J. Am. Chem. Soc.* 1990, 112, 4633. Lin, C. H.; Beale, J. M.; Hurley, L. H. *Biochemistry* 1991, 30, 3597.

(8) Lin, C. H.; Sun, D.; Hurley, L. H. *Chem. Res. Toxicol.* 1991, 4, 26. Lee, C.-S.; Sun, D.; Kizu, R.; Hurley, L. H. *Chem. Res. Toxicol.* 1991, 4, 203.

(9) Boger, D. L.; Invergo, B. J.; Coleman, R. S.; Zarrinmayeh, H.; Kitos, P. A.; Thompson, S. C.; Leong, T.; McLaughlin, L. W. *Chem.-Biol. Interact.* 1990, 73, 29.

(10) Boger, D. L.; Coleman, R. S.; Invergo, B. J. *J. Org. Chem.* 1987, 52, 1521.

(11) For recent reviews, see: Boger, D. L. In *Heterocycles in Bio-Organic Chemistry*; Bergman, J., Van der Plas, H. D., Simonyi, M., Eds.; Royal Society of Chemistry: Cambridge, 1991; p 103. Boger, D. L. In *Advances in Heterocyclic Natural Products Synthesis*; Pearson, W. H., Ed.; JAI Press: Greenwich, 1992; Vol. 2, pp 1-177.

(12) Dickerson, R. E. In *Structure and Methods, DNA and RNA*; Sarma, R. H., Sarma, M. H., Eds.; Adenine Press: Schenectady, NY, 1991; Vol. 3, p 1. Nelson, H. C. M.; Finch, J. T.; Luisi, B. F.; Klug, A. *Nature (London)* 1987, 330, 221. Coll, M.; Frederick, C. A.; Wang, A. H.-J.; Rich, A. *Proc. Natl. Acad. Sci. U.S.A.* 1987, 84, 8385. Coll, M.; Aymami, J.; van der Marel, G. A.; van Boom, J. H.; Rich, A.; Wang, A. H.-J. *Biochemistry* 1989, 28, 310.

(13) Boger, D. L.; Coleman, R. S.; Invergo, B. J.; Sakya, S. M.; Ishizaki, T.; Munk, S. A.; Zarrinmayeh, H.; Kitos, P. A.; Thompson, S. C. *J. Am. Chem. Soc.* 1990, 112, 4623.

(14) Boger, D. L.; Munk, S. A.; Zarrinmayeh, H.; Ishizaki, T.; Haught, J.; Bina, M. *Tetrahedron* 1991, 47, 2661.


(15) Boger, D. L.; Munk, S. A.; Zarrinmayeh, H. *J. Am. Chem. Soc.* 1991, 113, 3980.

(16) Boger, D. L.; Zarrinmayeh, H.; Munk, S. A.; Kitos, P. A.; Sun-tornwat, O. *Proc. Natl. Acad. Sci. U.S.A.* 1991, 88, 1431.

(17) Boger, D. L.; Munk, S. A.; Ishizaki, T. *J. Am. Chem. Soc.* 1991, 113, 2779. Boger, D. L.; Ishizaki, T. *Tetrahedron Lett.* 1990, 31, 793.

(18) Boger, D. L.; Ishizaki, T.; Sakya, S. M.; Munk, S. A.; Kitos, P. A.; Jin, Q.; Besterman, J. M. *BioMed. Chem. Lett.* 1991, 1, 115.

* Address correspondence to this author at Department of Chemistry, The Scripps Research Institute, 10666 North Torrey Pines Road, La Jolla, CA 92037.



face of the agents. In addition, studies of TACDPI_n (8–10, $n = 1$ –3) establish a significant enhancement of the non-covalent minor groove binding affinity through introduction of an electropositive substituent and stabilizing electrostatic interactions.

Synthesis of ACDPI_n and TACDPI_n. The repeating monomer units of agents employed in the study were prepared through functionalization of the readily accessible *N*³-*tert*-butyloxycarbonyl derivative of CDPI₁ (11) which in turn has been prepared in five steps (55% overall yield)¹⁰ from available materials. Low-temperature nitration of 11 cleanly afforded 12 (82%). Subsequent reduction of the nitro group provided the *N*³-*tert*-butyloxycarbonyl derivative of ACDPI₁ (4, 77–93%) and protection of the free amine as its benzyloxycarbonyl derivative provided 13 (83%), Scheme I. Lithium hydroxide hydrolysis of the methyl ester of 13 conducted under an inert atmosphere in the presence of sodium dithionite

provided 15 (99%). Acid-catalyzed removal of the *N*³-*tert*-butyloxycarbonyl group of 13 provided 14 as an unstable salt which was coupled directly with 15 through use of the water-soluble 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide (EDCI) to provide 16 (65%). The coupling reaction and those to follow were run necessarily as suspensions in dimethylformamide for extended reaction times (48–60 h). The subsequent removal of reagent-derived materials from the coupling product was effectively accomplished by aqueous acid trituration of the insoluble reaction product followed by an organic solvent trituration, and final purification was accomplished by column chromatography. Catalytic hydrogenolysis of 16 removed the two benzyloxycarbonyl groups and provided ACDPI₂ (5, 81%). Acid-catalyzed removal of the *tert*-butyloxycarbonyl group of 16 followed by immediate EDCI-promoted coupling of the resulting unstable hydrochloride salt with 15 provided 17 (89%), and subsequent catalytic hydrogenolysis provided ACDPI₃ (6, 63%). The agents became increasingly less soluble in organic solvents as their size increased. This proved especially true of the free amines 6 and 7, and the modest conversions in the final hydrogenolysis reactions reflect the difficulty in the chromatographic purification of the agents and not an

(19) Boger, D. L.; Ishizaki, T.; Kitos, P. A.; Suntornwat, O. *J. Org. Chem.* 1990, 55, 5823. Boger, D. L.; Ishizaki, T.; Wysocki, R. J., Jr.; Munk, S. A.; Kitos, P. A.; Suntornwat, O. *J. Am. Chem. Soc.* 1989, 111, 6461.

(20) Boger, D. L.; Wysocki, R. J., Jr.; Ishizaki, T. *J. Am. Chem. Soc.* 1990, 112, 5230.





Figure 1.

inherent problem in the deprotection reaction. In a similar fashion, acid-catalyzed deprotection of 17 followed by EDCI-promoted coupling of the resultant hydrochloride salt with 15 provided 18 (72%). Subjection of 18 to the conditions of catalytic hydrogenolysis provided ACDPI₄ (7, 40%).

The final series of agents, TACDPI_n (8-10), was prepared through exhaustive methylation of the free amines 4-6, eq 1. The resulting agents became increasingly more water soluble and less organic soluble as the size of the agent and number of quaternary amines increased. For TACDPI₃ and TACDPI₂, this precluded isolation by standard chromatographic methods and required that the final purification be conducted by recrystallization for which no deliberate effort was made to ensure full recovery of the desired agent. Consequently, the conversions re-



ported for the preparation of 9 and 10 exceed that detailed for their isolation. The trimer agent, TACDPI₃ (10), proved particularly difficult to crystallize and was found to be optimally conducted with the methanesulfonate salt derived from exhaustive methylation with dimethylsulfate.

DNA Binding Studies. The relative and absolute binding constants of the agents were determined by fluorescence measurements of the displacement of prebound ethidium bromide from DNA.^{9,21} Under the conditions employed, the agents do not interfere with the measurement of the characteristic fluorescence loss due to the displacement of DNA-bound ethidium bromide. In contrast to prior agents studied using this technique, the binding of CDPI₃ to poly[dA]-poly[dT] and poly[d(A-T)]-poly[d(A-T)] follows an ideal model for agent non-competitive binding.²² This first was evident in studies⁹ with CDPI₃ (2, $r = 0.2$) and PDE-I₂ ($r = 0.27$) upon examination of the linear plots of percent fluorescence versus r , $[\text{agent}]_T/[\text{base-pair}]_T$ where $[\text{agent}]_T$ and $[\text{base-pair}]_T$ constitute the total agent concentration and the total base-pair concentration employed in the assay. The X-intercept of the linear plots was found to correspond to the ideal $[\text{agent}]/[\text{base-pair}]$ ratios of 0.2 and 0.27, respectively. This is illustrated with the *tert*-butyloxycarbonyl derivative of CDPI₃ (3) examined in the present study (Figure 2). This corresponds to an agent/base-pair ratio of 1/5 for CDPI₃ and nicely accommodates the expected minor groove binding which spans five base-pairs. Consequently, the noncompetitive binding of CDPI₃ proceeds with the linear displacement of prebound ethidium bromide in a manner that permits the accurate quantification of the DNA-bound agent and the accurate measurement of absolute binding constants according to eq 2 at 50% fluorescence.⁹


$$K = \frac{1}{[\text{agent}]_T - 0.5[\text{base-pair}]_T r} \quad (2)$$

r = agent/base-pair binding site size

The plots of percent fluorescence versus r for the agents in the present study proved linear, and the X-intercepts

(21) Morgan, A. R.; Lee, J. S.; Pulleyblank, D. E.; Murray, N. L.; Evans, D. H. *Nucl. Acids Res.* 1979, 7, 547.

(22) Baguley, B. C.; Denny, A. W.; Atwell, G. J.; Cain, B. F. *J. Med. Chem.* 1981, 24, 170.

Figure 2. Percent fluorescence versus $[3]/[\text{base-pair}]$.Table I. Binding Constants and Estimated Free Energies of Binding^a

agent	K_b (M^{-1})	ΔG° (kcal/mol, 298 K)	agent	K_b (M^{-1})	ΔG° (kcal/mol, 298 K)	agent ^b	K_b (M^{-1})	ΔG° (kcal/mol, 298 K)
Poly[dA]-Poly[dT]								
CDPI ₁	6.4×10^4	-6.6	ACDPI ₁	5.7×10^3	-5.1	TACDPI ₁	3.8×10^6	-7.6
CDPI ₂	3.2×10^5	-7.5	ACDPI ₂	2.8×10^4	-6.1	TACDPI ₂	1.4×10^7	-9.8
CDPI ₃	1.8×10^7	-9.9	ACDPI ₃	9.6×10^5	-8.2	TACDPI ₃	1.3×10^8	-11.1
CDPI ₄	1.4×10^6	-8.4	ACDPI ₄	5.6×10^5	-7.8			
CDPI ₅	2.1×10^6	-8.6						
3	1.5×10^7	-9.8						
Poly[d(A-T)]-Poly[d(A-T)]								
CDPI ₁	6.1×10^4	-6.5	ACDPI ₁	4.3×10^3	-5.0	TACDPI ₁	4.5×10^5	-7.7
CDPI ₂	9.6×10^4	-6.8	ACDPI ₂	2.1×10^4	-5.9	TACDPI ₂	2.1×10^7	-10.0
CDPI ₃	8.9×10^6	-9.5	ACDPI ₃	1.4×10^6	-8.4	TACDPI ₃	5.4×10^8	-11.9
CDPI ₄	6.7×10^5	-8.0	ACDPI ₄	2.2×10^5	-7.3			
CDPI ₅	6.7×10^5	-8.0						
3	7.3×10^6	-9.3						
Poly[dG]-Poly[dC]								
CDPI ₁	5.1×10^4	-6.4	ACDPI ₁	3.2×10^3	-4.8	TACDPI ₁	2.1×10^4	-5.9
CDPI ₂	6.9×10^4	-6.6	ACDPI ₂	4.3×10^3	-5.0	TACDPI ₂	1.0×10^6	-8.2
CDPI ₃	2.0×10^5	-7.2	ACDPI ₃	1.4×10^5	-7.0	TACDPI ₃	1.6×10^6	-8.4
CDPI ₄	4.1×10^5	-7.7	ACDPI ₄	1.0×10^5	-6.8			
CDPI ₅	4.9×10^5	-7.8						
3	2.1×10^5	-7.3						

^a Unless indicated otherwise, $r = 0.6, 0.3, 0.2,$ and 0.25 for $n = 1, 2, 3,$ and 4 or $5,$ respectively. ^b For TACDPI₂, $r = 0.23$; for TACDPI₃, $r = 0.11$ as determined from the X-intercept of plots of percent fluorescence vs r .

were employed to determine the characteristic r value which, in general, corresponded to the expected ideal value. The results of the DNA binding studies are presented in Table I, and the binding constants were calculated using the noncompetitive binding model⁹ with r values of 0.6, 0.3, 0.2, and 0.25 for the agent monomer, dimer, trimer, and tetramer, respectively, unless otherwise indicated. In initial studies and for comparison purposes, the absolute binding constants for CDPI₃ were calculated using a conventional competitive binding model²² and did not differ significantly from those calculated using the noncompetitive binding model.⁹

ACDPI_{*n*}. Consistent with past observations with CDPI_{*n*}⁹ (Figure 3A), the ACDPI₃ binding constant for poly[dA]-poly[dT] proved largest within the ACDPI_{*n*} series of agents studied, and this is apparent from the plot of $\log K_b$ versus agent, Figure 3B: ACDPI₄ < ACDPI₃ > ACDPI₂ > ACDPI₁. As discussed in detail elsewhere for the CDPI_{*n*} oligomers, we have interpreted the unexpected behavior of the higher oligomer agents to represent kinetic binding within the minor groove in partial-bound forms, i.e. ACDPI₂-bound or ACDPI₃-bound ACDPI₄.⁹ This may be attributed to at least two features of the agents. As the size of the oligomeric agents surpass the trimer, a large number of accessible conformations are available to the

agent in addition to the helical conformation required for full agent binding. This becomes more pronounced as the size of the agent increases and represents a barrier to achieving full structure binding. Perhaps more importantly, the trimer binding covers five base-pairs constituting half of a full B-DNA helix turn. For a relatively rigid agent such as ACDPI_{*n*} or CDPI_{*n*}, this represents the largest accessible minor groove DNA binding site that permits both ends of the agent to achieve near synchronous binding through a helical conformation. For larger agents including ACDPI₄ and CDPI₄, both ends of the agent may not bind synchronously since the binding termini lie on opposite faces of the helix. Moreover, the relatively rigid structure of the agents, the depth to which the agents penetrate into the minor groove, and its narrow width require that the agents undergo decomplexation and rebinding or that the DNA undergo substantial local unwinding in order to permit the conformational interconversion between partial and full bound agents. In the prior studies with CDPI_{*n*},⁹ we established through thermal denaturation studies that prolonged incubation of the tetramer agent with DNA (10 d versus 30 min) did lead to a complex that was more stable than the initial kinetic complex, that the slow interconversion of the two distinct complexes could be followed over the prolonged incubation, and that the latter






Figure 3.



● Affinity

$$n = 3 > 4, 5 > 2 > 1$$



● Specificity

$$AT > GC \quad \text{for } n = 3$$

$$\Delta\Delta G^\circ = 1.2 - 2.7 \text{ kcal}$$

poly[dA]poly[dT]

$$\Delta G^\circ (298^\circ K, \text{ kcal/mol})$$

R	n = 1	2	3	4	5
NH ₂	-5.1	-6.1	-8.2	-7.8	
H	-6.6	-7.5	-9.9	-8.4	-8.6
⁺ NMe ₃	-7.6	-9.8	-11.1		

n = 3 $\Delta G^\circ (298^\circ K, \text{ kcal/mol})$

R	poly[dA]- poly[dT]	poly[dG]- poly[dC]	$\Delta\Delta G^\circ$
NH ₂	-8.2	-7.0	-1.2
H	-9.9	-7.2	-2.7
⁺ NMe ₃	-11.1	-8.4	-2.7

Figure 4.

complex was more stable than that derived from the corresponding trimer agent. We assume that ACDPI₄ is behaving in a comparable manner, see Figure 3, parts A and B. Consistent with the prior observations made with CDPI_n, the experimental results indicated that ACDPI₃ is the most effective binding agent within the ACDPI_n series and possesses the optimal combination of size and structural features that facilitate kinetically rapid and thermodynamically stable minor groove binding.

Identical trends and nearly identical binding constants for ACDPI_n were observed with poly[d(A-T)]-poly[d(A-T)]. In marked contrast, the binding of ACDPI_n with poly-




Figure 5. Two views of d(A)₂₋₅-d(T)₂₋₅:CDPI, d(A)₂₋₅-d(T)₂₋₅:ACDPI, and d(A)₂₋₅-d(T)₂₋₅:TACDPI taken from d(A)₁₀-d(T)₁₀:CDPI₃, d(A)₁₀-d(T)₁₀:ACDPI₃, and d(A)₁₀-d(T)₁₀:TACDPI₃ models (MacroModel, AMBER force field supplemented with agent parameters).

[dG]-poly[dC] was substantially reduced, although a similar trend in binding affinity was observed: ACDPI₄ < ACDPI₃ > ACDPI₂ > ACDPI₁.

Perhaps more important is the comparison of the ACDPI_n versus CDPI_n agents. The introduction of an amino group onto the outer face of CDPI_n resulted in a substantial reduction in the agent DNA minor groove binding affinity, Figure 4, without altering the inherent AT binding selectivity. This may be attributed in part to the strategic placement of the amino group on the outer face of the DNA-agent complex between the walls of the

minor groove and proximal to phosphates in the DNA backbone, cf. Figure 5. At a pH of 8 as employed in the assay, the ACDPI_n agents possess a free amine resulting in an apparent and substantial destabilizing electrostatic interaction with the negatively charged phosphate backbone of DNA.

TACDPI_n. Having established that the introduction of an electronegative substituent onto the peripheral face of CDPI_n diminished its DNA binding affinity, a complementary class of agents bearing an electropositive C-5 substituent was examined. The study of the series of TACDPI_n agents in which the C-5 primary amine of ACDPI_n was converted to a quaternary amine through exhaustive methylation proved revealing. Consistent with expectations, the noncovalent binding affinity of the agents increased as the size of the agent was increased, TACDPI₃ > TACDPI₂ > TACDPI₁. Similar to the trends observed with CDPI_n and ACDPI_n, TACDPI_n exhibited a substantial binding preference for AT-rich versus GC-rich DNA, and this preference was most evident with the trimer, Figure 3C ($n = 3$, $\Delta\Delta G^\circ = -2.7$ to -3.5 kcal). In addition, the relative binding affinity of the agents substantially exceeded that of ACDPI_n and significantly surpassed that of the parent CDPI_n agents. We attribute this increased DNA binding affinity to the stabilizing electrostatic interaction between the negatively charged phosphates in the DNA backbone and the strategically placed, positively charged ammonium group on the peripheral face of agent, Figure 5. Importantly, this increased binding affinity derived from stabilizing electrostatic interactions is of such a magnitude that it overrides the effect of the increased water solubility of the agents that would be expected to diminish the inherent hydrophobic binding affinity.

Role of the Terminal Urethane. Finally, the relative and absolute binding of the two CDPI_n agents, 2 versus 3, proved indistinguishable within the experimental error inherent in the measurements for each of the three DNAs examined indicating that the terminal urethane of 2, like that found in (+)-CC-1065, is not contributing to the affinity or specificity of the DNA minor groove binding.

Conclusions. Comparable to observations made with CDPI_n,⁹ examination of the ACDPI_n oligomers revealed that ACDPI₃ is the optimal DNA minor groove binding agent in the series, that the tetramer and higher oligomers exhibit DNA binding properties intermediate between those of the corresponding dimer and trimer, and that the agents exhibit a selectivity for AT-rich versus GC-rich DNA which is most pronounced with ACDPI₃. Similarly, the examination of the TACDPI_n oligomers revealed a pronounced AT-rich versus GC-rich binding selectivity. The direct comparison of CDPI_n with ACDPI_n revealed that the introduction of a C-5 amino substituent onto the peripheral face of the agent resulted in a substantial reduction in the DNA minor groove binding affinity that we attribute to the introduction of destabilizing electrostatic interactions. In contrast, the comparison of CDPI_n with TACDPI_n revealed that the introduction of a C-5 quaternary amine resulted in a substantial enhancement in the DNA binding affinity attributable to the introduction of stabilizing electrostatic interactions.²³

Experimental Section

Methyl 3-(*tert*-Butyloxycarbonyl)-5-nitro-1,2-dihydro-3H-pyrrolo[3,2-*e*]indole-7-carboxylate (12). A solution of 11¹⁰

(600 mg, 1.9 mmol) in dry nitromethane (10 mL) was treated with concentrated HNO₃ (0.20 mL, 3.1 mmol, 1.6 equiv) at 0 °C (15 min). Additional HNO₃ (0.05 mL, 0.78 mmol, 0.4 equiv) was added, and the mixture was stirred for 1.5 h at 0 °C. The mixture was poured into water (20 mL) and extracted with CH₂Cl₂ (4 × 15 mL). The combined organic phase was dried (Na₂SO₄) and concentrated in vacuo. Chromatography (2 cm × 13 cm, gradient elution with 0–10% EtOAc–hexane) afforded 12 (562 mg, 685 mg theoretical, 82%) as an orange-yellow crystalline solid: mp 198–200.5 °C (orange needles, hexane–EtOAc); ¹H NMR (CDCl₃, 300 MHz) δ 10.30 (br s, 1 H, NH), 8.95 (br s, 1 H, C4-H), 7.20 (d, 1 H, $J = 1$ Hz, C8-H), 4.20 (t, 2 H, $J = 8.5$ Hz, ArCH₂CH₂NR), 4.02 (s, 3 H, CO₂CH₃), 3.40 (t, 2 H, $J = 8.5$ Hz, ArCH₂CH₂NR), 1.62 (br s, 9 H, *t*Bu); ¹³C NMR (CDCl₃, 75 MHz) δ 160.7, 151.9, 136.7, 132.9, 131.4, 130.1, 126.9, 126.2, 110.0, 109.0, 106.3, 52.3, 47.7, 28.2, 26.5; IR (KBr) ν_{\max} 3463, 2975, 1701, 1654, 1636, 1588, 1540 cm⁻¹; EIMS m/e (relative intensity) 361 (M⁺, 4), 305 (49), 261 (16), 229 (19), 57 (base); CIMS (isobutane) m/e (relative intensity) 362 (M⁺ + H, base); EIHRMS m/e 361.1269 (C₁₇H₁₉N₃O₆ requires 361.1274).

Anal. Calcd for C₁₇H₁₉N₃O₆: C, 56.51; H, 5.30; N, 11.63. Found: C, 56.42; H, 5.43; N, 11.43.

A minor side product, methyl 3-(*tert*-butyloxycarbonyl)-8-nitro-1,2-dihydro-3H-pyrrolo[3,2-*e*]indole-7-carboxylate was isolated in less than 10% yield: mp 216–218 °C dec (yellow fluffy solid, hexane–EtOAc); ¹H NMR (DMSO-*d*₆, 300 MHz) δ 13.16 (br s, 1 H, NH), 7.94 (br s, 1 H, C4-H), 7.32 (d, 1 H, $J = 9$ Hz, C5-H), 3.92 (t, 2 H, $J = 8$ Hz, ArCH₂CH₂NR), 3.93 (s, 3 H, CO₂CH₃), 3.31 (t, 2 H, $J = 8$ Hz, ArCH₂CH₂NR), 1.49 (s, 9 H, *t*Bu); ¹³C NMR (DMSO-*d*₆, 75 MHz) δ 160.2, 152.0, 140.0, 131.0, 128.0, 127.3, 121.0, 117.2, 114.5, 112.5, 80.1, 53.0, 47.6, 28.0, 27.0; IR (KBr) ν_{\max} 3432, 2974, 1692, 1522, 1506 cm⁻¹.

Methyl 5-Amino-3-(*tert*-butyloxycarbonyl)-1,2-dihydro-3H-pyrrolo[3,2-*e*]indole-7-carboxylate (4). A solution of 12 (690 mg, 1.96 mmol) in dry THF (20 mL) was treated with 10% Pd–C (1.7 g, 0.25 wt equiv) and placed under 1 atm of H₂ (12 h). The catalyst was removed by filtration through Celite, and the solvent was removed in vacuo. Chromatography (after dry packing with 20 g of SiO₂, 2 cm × 18 cm, gradient elution with 5–22% EtOAc–hexane) afforded ACDPI₁ (4, 500 mg, 649 mg theoretical, 77%; typically 93–77%) as pale green solid: mp 215 °C dec (light green plates, EtOAc–hexane); ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.45 (br s, 1 H, NH), 7.20 (br s, 1 H, C4-H), 6.90 (d, 1 H, $J = 1$ Hz, C8-H), 5.44 (br s, 2 H, NH₂), 3.94 (t, 2 H, $J = 8.5$ Hz, ArCH₂CH₂NR), 3.88 (s, 3 H, CO₂CH₃), 3.08 (t, 2 H, $J = 8.5$ Hz, ArCH₂CH₂NR), 1.51 (br s, 9 H, *t*Bu); ¹³C NMR (DMSO-*d*₆, 75 MHz) δ 162.5, 152.5, 137.5, 134.0, 127.0, 125.2, 124.8, 108.5, 106.2, 97.2, 79.8, 52.2, 48.5, 28.6, 26.0; IR (KBr) ν_{\max} 3443, 3370, 3327, 2977, 2933, 1689, 1597, 1531, 1516 cm⁻¹; EIMS m/e (relative intensity) 331 (M⁺, 20), 243 (base), 198 (18), 171 (16), 143 (12), 57 (67); CIMS (isobutane) m/e 332 (M⁺ + H, base); EIHRMS m/e 331.1525 (C₁₇H₂₁O₄N₃ requires 331.1532).

Anal. Calcd for C₁₇H₂₁N₃O₄: C, 61.62; H, 6.30; N, 12.68. Found: C, 61.62; H, 6.65; N, 12.84.

Methyl 5-[(Benzyloxycarbonyl)amino]-3-(*tert*-butyloxycarbonyl)-1,2-dihydro-3H-pyrrolo[3,2-*e*]indole-7-carboxylate (13). A solution of 4 (332 mg, 1.0 mmol) in THF (5 mL) at 0 °C was treated sequentially with K₂CO₃ (279 mg, 2.02 mmol, 2.0 equiv) and benzyl chloroformate (0.16 mL, 1.11 mmol, 1.1 equiv) and stirred vigorously at 0 °C for 3 h. Additional benzyl chloroformate (0.13 mL, 0.91 mmol, 0.9 equiv) was added, and the mixture was stirred at 0 °C (1 h) and 23 °C (1 h). The reaction mixture was diluted with H₂O (50 mL) and extracted with CH₂Cl₂ (3 × 50 mL). The combined organic phase was dried (Na₂SO₄) and concentrated in vacuo. Chromatography (2 cm × 16 cm, gradient elution with 0–18% EtOAc–hexane) provided 13 (389 mg, 461 mg theoretical, 83%) as a white fluffy solid: mp 185–186.5 °C (fine white needles, EtOAc–hexane); ¹H NMR (CDCl₃, 300 MHz) δ 10.22 (br s, 1 H, NH), 7.75 (br s, 1 H, C4-H), 7.38–7.34 (m, 5 H, PhH), 7.03 (d, 1 H, $J = 1$ Hz, C8-H), 5.24 (s, 2 H, PhCH₂), 4.07 (t, 2 H, $J = 8.5$ Hz, ArCH₂CH₂NR), 3.92 (s, 3 H, CO₂CH₃), 3.21 (t, 2 H, $J = 8.5$ Hz, ArCH₂CH₂NR), 1.55 (br s, 9 H, *t*Bu); IR (KBr) ν_{\max} 3314, 3154, 2976, 1712, 1697, 1686, 1636, 1609, 1550, 1510 cm⁻¹; EIMS m/e (relative intensity) 465 (M⁺, 4), 409 (20), 274 (30), 91 (base); CIMS (isobutane) m/e 466 (M⁺ + H, base); EIHRMS m/e 465.1888 (C₂₆H₂₇N₃O₆ requires 465.1900).

(23) In vitro cytotoxic activity for the agents (IC₅₀, μ g/mL, L1210): CDPI₁ (>50), CDPI₂ (>50), CDPI₃ (0.6), CDPI₄ (0.007), CDPI₅ (>20), ACDPI₁ (>1), ACDPI₂ (>1), ACDPI₃ (>1), TACDPI₁ (>50), TACDPI₂ (>50), TACDPI₃ (>50).

Anal. Calcd for $C_{26}H_{27}N_3O_6$: C, 64.51; H, 5.85; N, 9.03. Found: C, 64.54; H, 6.18; N, 9.21.

5-[(Benzyloxycarbonyl)amino]-3-(*tert*-butyloxycarbonyl)-1,2-dihydro-3*H*-pyrrolo[3,2-*e*]indole-7-carboxylic Acid (15). A solution of 13 (81.6 mg, 0.82 mmol) in THF-H₂O (3:1, 3 mL) under argon was treated with LiOH-H₂O (172 mg, 4.10 mmol, 5.0 equiv) and sodium dithionite (285 mg, 1.64 mmol, 2.0 equiv) and stirred at 23 °C (72 h). The reaction mixture was poured into H₂O (15 mL), acidified to pH 4 with the addition of 10% aqueous HCl, and extracted with EtOAc (4 × 25 mL). The combined organic layer was washed with saturated aqueous NaCl (15 mL), dried (Na₂SO₄), and concentrated in vacuo. The crude product was slurried with silica gel (550 mg) in CH₂Cl₂, the solvent was removed in vacuo, and the dry silica gel was loaded onto a flash chromatography column. Chromatography (2 cm × 9 cm, gradient elution with 50–100% EtOAc-hexane then 10% MeOH-EtOAc) provided 15 (367 mg, 370 mg theoretical, 99%) as a light green solid: mp 205–207 °C dec (greenish white flakes, EtOAc); ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.55 (s, 1 H, NH), 9.60 (s, 1 H, CONH), 8.48 (br s, 1 H, C4-H), 7.49–7.31 (m, 5 H, PhH), 6.94 (d, 1 H, *J* = 1.5 Hz, C8-H), 5.20 (s, 2 H, PhCH₂), 3.99 (t, 2 H, *J* = 8.4 Hz, C1-H₂), 3.15 (t, 2 H, *J* = 8.4 Hz, C2-H₂), 1.52 (br s, 9 H, *t*Bu); IR (KBr) ν_{\max} 3348, 2976, 1696, 1548 cm⁻¹; EIMS *m/e* (relative intensity) 451 (M⁺, 2), 108 (45), 91 (34), 56 (base); CIMS (isobutane) *m/e* 452 (M⁺ + H, base); EIHRMS *m/e* 451.1752 (C₂₄H₂₅N₃O₆ requires 451.1743).

Methyl 5-[(Benzyloxycarbonyl)amino]-3-[[5'-(benzyloxycarbonyl)amino]-3'-[(*tert*-butyloxycarbonyl)-1',2'-dihydro-3'*H*-pyrrolo[3',2'-*e*]indol-7'-yl]carbonyl]-1,2-dihydro-3*H*-pyrrolo[3,2-*e*]indole-7-carboxylate (16). The agent 13 (219 mg, 0.47 mmol) was treated with a solution of 3 M HCl in EtOAc (5 mL), and the mixture was stirred under argon at 23 °C (1 h). Removal of the solvent in vacuo provided the crude unstable hydrochloride salt 14 as a gray solid in quantitative yield.

A solution of 14 (143 mg, 0.36 mmol), 15 (179 mg, 0.40 mmol, 1.2 equiv), EDCI (224 mg, 1.17 mmol, 3.3 equiv), and NaHCO₃ (262 mg, 3.12 mmol, 8.7 equiv) in dry DMF (3.0 mL) was stirred vigorously under nitrogen at 23 °C (49 h). The reaction mixture was poured into H₂O (25 mL) and acidified to pH 4–5 with the addition of 10% aqueous HCl. The mixture was extracted with EtOAc (4 × 100 mL), and the combined organic layer was washed with saturated aqueous NaCl (30 mL), dried (Na₂SO₄), and concentrated in vacuo. Chromatography (2 cm × 19 cm, gradient elution with 0–40% EtOAc-hexane) gave 16 (187 mg, 287 mg theoretical, 65%) as a pale white solid: mp 228–229.5 °C dec (fine white flakes, CH₂Cl₂-hexane); ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.74 (br s, 1 H, NH), 11.64 (br s, 1 H, NH), 9.77 (br s, 1 H, CONH), 9.64 (br s, 1 H, CONH), 9.00 (br s, 1 H, C4-H), 8.45 (very br s, 1 H, C4'-H), 7.50–7.36 (m, 10 H, PhH), 7.11 (d, 1 H, *J* = 1.6 Hz, C8-H), 6.97 (d, 1 H, *J* = 1.6 Hz, C8-H), 5.21 (s, 4 H, PhCH₂), 4.60 (t, 2 H, *J* = 7.9 Hz, C2-H₂), 3.99 (t, 2 H, *J* = 7.9 Hz, C2'-H₂), 3.88 (s, 3 H, CO₂CH₃), 3.37 (t, 2 H, *J* = 7.9 Hz, C1-H₂), 3.18 (t, 2 H, *J* = 7.9 Hz, C1'-H₂), 1.54 (s, 9 H, *t*Bu); IR (KBr) ν_{\max} 3424, 1702, 1528, 1388, 1244, 1138, 736 cm⁻¹; FABMS (*m*-nitrobenzyl alcohol) *m/e* 799 (M⁺ + H); FABHRMS (*m*-nitrobenzyl alcohol) *m/e* 799.2877 (C₄₄H₄₂N₆O₉ + H⁺ requires 799.3091).

Anal. Calcd for C₄₄H₄₂N₆O₉: C, 66.16; H, 5.30; N, 10.52. Found: C, 65.08; H, 4.97; N, 10.55.

Methyl 5-[(Benzyloxycarbonyl)amino]-3-[[5'-(benzyloxycarbonyl)amino]-3'-[[5''-(benzyloxycarbonyl)amino]-3'''-(*tert*-butyloxycarbonyl)-1'''',2''-dihydro-3'''*H*-pyrrolo[3'''',2''-*e*]indol-7''-yl]carbonyl]-1',2'-dihydro-3'*H*-pyrrolo[3',2'-*e*]indol-7'-yl]carbonyl]-1,2-dihydro-3*H*-pyrrolo[3,2-*e*]indole-7-carboxylate (17). A solution of 16 (50.4 mg, 0.063 mmol) in 3 M HCl in EtOAc (1 mL) was stirred under N₂ for 30 min. Removal of the solvent in vacuo afforded the crude hydrochloride salt as a green solid.

The crude salt (0.063 mmol), 15 (34 mg, 0.075 mmol, 1.2 equiv), EDCI (36 mg, 0.19 mmol, 3.0 equiv), and NaHCO₃ (42 mg, 0.50 mmol, 8.0 equiv) in dry DMF (1.5 mL) under N₂ were stirred at 23 °C (48 h). The reaction mixture was poured into H₂O (25 mL), acidified to pH 4 with the addition of 10% aqueous HCl, and extracted with EtOAc (4 × 35 mL). The organic layer was washed with saturated aqueous NaCl (20 mL), dried (Na₂SO₄), and concentrated in vacuo. Chromatography (2 cm × 9 cm, 20–100% EtOAc-hexane gradient elution) provided 17 (63.3 mg, 70.9 mg

theoretical, 89%) as a pale white solid: mp > 275 °C dec (fine white flakes, EtOAc); ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.77 (br s, 1 H, NH), 11.73 (br s, 1 H, NH), 11.65 (br s, 1 H, NH), 9.81 (br s, 1 H, CONH), 9.77 (br s, 1 H, CONH), 9.64 (br s, 1 H, CONH), 9.00 (br s, 1 H, C4-H), 8.96 (br s, 1 H, C4'-H), 8.45 (very br s, 1 H, C4''-H), 7.49–7.32 (m, 15 H, PhH), 7.14 (s, 1 H, C8''-H or C8'-H), 7.12 (s, 1 H, C8'-H or C8''-H), 7.02 (s, 1 H, C8-H), 5.20 (s, 6 H, PhCH₂), 4.64 (t, 4 H, *J* = 7.6 Hz, C2-H₂ and C2'-H₂), 4.03 (t, 2 H, *J* = 7.6 Hz, C2''-H₂), 3.87 (s, 3 H, CO₂CH₃), 3.40 (m, 4 H, C1-H₂ and C1'-H₂), 3.23 (t, 2 H, *J* = 6.2 Hz, C1''-H₂), 1.52 (br s, 9 H, *t*Bu); IR (KBr) ν_{\max} 3426, 2934, 1700, 1636, 1524 cm⁻¹; FABMS (DTT/DTE) *m/e* 1132 (M⁺ + H).

Anal. Calcd for C₆₃H₅₇N₉O₁₂: C, 66.83; H, 5.07; N, 11.13. Found: C, 66.47; H, 5.28; N, 11.47.

Methyl 5-[(Benzyloxycarbonyl)amino]-3-[[5'-(benzyloxycarbonyl)amino]-3'-[[5''-(benzyloxycarbonyl)amino]-3'''-(*tert*-butyloxycarbonyl)-1'''',2''-dihydro-3'''*H*-pyrrolo[3'''',2''-*e*]indol-7''-yl]carbonyl]-1',2'-dihydro-3'*H*-pyrrolo[3',2'-*e*]indol-7'-yl]carbonyl]-1,2-dihydro-3*H*-pyrrolo[3,2-*e*]indole-7-carboxylate (18). A solution of 17 (50.8 mg, 0.045 mmol) in 3 M HCl in EtOAc (2 mL) under N₂ was stirred at 23 °C (45 min). Removal of solvent in vacuo provided the crude unstable hydrochloride salt (48 mg, 48 mg theoretical, 100%) as a dark green solid.

The crude hydrochloride salt (0.045 mmol), 15 (20.3 mg, 0.048 mmol, 1.1 equiv), EDCI (26 mg, 0.14 mmol, 3.0 equiv), and NaHCO₃ (30.2 mg, 0.36 mmol, 8.0 equiv) in dry DMF (1.5 mL) under N₂ were stirred vigorously at 23 °C (60 h). The reaction mixture was poured into H₂O (5 mL) and acidified to pH 4 with the addition of 10% aqueous HCl. The mixture was slurried, and the suspended solid was collected by centrifugation. The solid was washed with H₂O (3 × 5 mL) and EtOAc (2 × 5 mL). The crude product was dry packed onto a flash chromatography column. Chromatography (2 cm × 12 cm, gradient elution with 50–100% EtOAc-hexane and then 5% MeOH-EtOAc) provided 18 (47.3 mg, 65.7 mg theoretical, 72%) as a light brown solid: mp > 275 °C (brown flakes, EtOAc-hexane); ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.77 (br s, 3 H, NH), 11.66 (br s, 1 H, NH), 9.83 (m, 3 H, CONH), 9.66 (br s, 1 H, CONH), 9.02 (br s, 3 H, C4-H, C4'-H, and C4''-H), 8.03 (very br s, 1 H, C4'''-H), 7.58–7.30 (m, 20 H, PhH), 7.15 (br s, 3 H, C8'-H, C8''-H, C8'''-H), 7.04 (br s, 1 H, C8-H), 5.23 (s, 8 H, PhCH₂), 4.70–4.60 (m, 4 H, C2-H₂, C2'-H₂), 4.20 (t, 2 H, *J* = 7.6 Hz, C2''-H), 4.04 (t, 2 H, *J* = 7.6 Hz, C2'''-H₂), 3.89 (s, 3 H, CO₂CH₃), 3.48–3.25 (m, 6 H, partially obscured by H₂O, C1-H₂, C1'-H₂, and C1''-H₂), 3.02 (t, 2 H, partially obscured by H₂O, C1'''-H₂), 1.55 (br s, 9 H, *t*Bu); IR (KBr) ν_{\max} 3856, 3752, 3320, 2950, 1702, 1622, 1524 cm⁻¹; FABMS (*m*-nitrobenzyl alcohol) *m/e* 1465 (M⁺ + H), 1487 (M⁺ + Na).

Methyl 5-Amino-3-[[5'-amino-3'-(*tert*-butyloxycarbonyl)-1',2'-dihydro-3'*H*-pyrrolo[3',2'-*e*]indol-7'-yl]carbonyl]-1,2-dihydro-3*H*-pyrrolo[3,2-*e*]indole-7-carboxylate (5). A solution of 16 (121 mg, 0.15 mmol) in dry THF (1.5 mL) under N₂ was treated with 10% palladium on carbon (42 mg, 0.35 wt equiv). The mixture was stirred under a H₂ atmosphere (1 atm) at 23 °C (66 h). The reaction mixture was filtered through Celite to remove the catalyst, and the filtrate was concentrated in vacuo. Chromatography (2 cm × 7.5 cm, 80% EtOAc-hexane, 1% MeOH-EtOAc and 5% MeOH, 15% hexane, 80% EtOAc eluant) provided ACDPI₂ (5, 64.8 mg, 79.5 mg theoretical, 81%) as a green crystalline solid: mp > 273 °C dec (green plates, CH₂Cl₂); ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.57 (s, 1 H, NH), 11.22 (s, 1 H, NH), 7.62 (s, 1 H, C4-H), 7.19 (br s, 1 H, C4'-H), 7.01 (s, 1 H, C8'-H), 6.84 (s, 1 H, C8-H), 5.48–5.44 (br d, 4 H, NH₂), 4.55 (t, 2 H, *J* = 8 Hz, C2-H₂), 3.95 (t, 2 H, *J* = 8 Hz, C2'-H₂), 3.89 (s, 3 H, CO₂CH₃), 3.21 (t, 2 H, *J* = 8 Hz, C1-H₂), 3.08 (t, 2 H, *J* = 8 Hz, C1'-H₂), 1.51 (br s, 9 H, *t*Bu); IR (KBr) ν_{\max} 3432, 1686, 1618, 1526, 1426, 1388, 1256, 1138 cm⁻¹; FABMS, (*m*-nitrobenzyl alcohol) *m/e* 530 (M⁺); FABHRMS (*m*-nitrobenzyl alcohol) *m/e* 531.2316 (C₂₈H₃₀N₆O₅ + H⁺ requires 531.2355).

Anal. Calcd for C₂₈H₃₀N₆O₅: C, 63.38; H, 5.70; N, 15.85. Found: C, 62.97; H, 5.74; N, 15.54.

Methyl 5-Amino-3-[[5'-amino-3'-[[5''-(benzyloxycarbonyl)-1'''',2''-dihydro-3'''*H*-pyrrolo[3'''',2''-*e*]indol-7''-yl]carbonyl]-1',2'-dihydro-3'*H*-pyrrolo[3',2'-*e*]indol-7'-yl]carbonyl]-1,2-dihydro-3*H*-pyrrolo[3,2-*e*]indole-7-

carboxylate (6). A solution of 17 (44.4 mg, 0.039 mmol) in dry THF (2.0 mL) was treated with 10% palladium on carbon (22.2 mg, 0.5 equiv) and placed under an atmosphere of H₂ (1 atm) at 23 °C (43 h). The reaction mixture was filtered through Celite, and the solvent was removed in vacuo. Chromatography (2 cm × 6 cm, 0–20% MeOH–EtOAc gradient elution) afforded ACDPI₃ (6, 17.9 mg, 28.6 mg theoretical, 63%) as a light green solid: mp > 275 °C dec (green plates, THF); ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.57 (br s, 1 H, NH), 11.33 (br s, 1 H, NH), 11.21 (br s, 1 H, NH), 7.63 (br s, 1 H, C4-H), 7.59 (br s, 1 H, C4'-H), 7.20 (br s, 1 H, C4''-H), 7.00 (s, 1 H, C8''-H or C8'-H), 6.95 (s, 1 H, C8'-H or C8''-H), 6.85 (s, 1 H, C8-H), 5.52–5.43 (m, 6 H, NH₂), 4.58 (m, 4 H, C2-H₂ and C2'-H₂), 3.95 (t, 2 H, *J* = 8.3 Hz, C2''-H₂), 3.88 (s, 3 H, CO₂CH₃), 3.22 (t, 4 H, *J* = 8.3 Hz, C1-H₂ and C1'-H₂), 3.08 (t, 2 H, *J* = 8.3 Hz, C1''-H₂), 1.50 (br s, 9 H, *t*Bu); IR (KBr) ν_{\max} 3426, 1700, 1618, 1508, 1342, 1140, 758 cm⁻¹; FABMS (*m*-nitrobenzyl alcohol) *m/e* 729 (M⁺); FABHRMS (*m*-nitrobenzyl alcohol) *m/e* 730.2939 (C₃₉H₃₉N₉O₆ + H⁺ requires 730.3101).

Anal. Calcd for C₃₉H₃₉N₉O₆: C, 64.18; H, 5.39; N, 17.27. Found: C, 62.46; H, 5.09; N, 17.53.

Methyl 5-Amino-3-[[5'-amino-3'-[[5''-amino-3''-[[5'''-amino-3'''-(*tert*-butyloxycarbonyl)-1'''',2'''-dihydro-3'''H-pyrrolo[3'''',2'''-e]indol-7'-yl]carbonyl]-1''',2''-dihydro-3'''H-pyrrolo[3''',2''-e]indol-7'-yl]carbonyl]-1'',2'-dihydro-3''H-pyrrolo[3'',2'-e]indol-7'-yl]carbonyl]-1,2-dihydro-3H-pyrrolo[3,2-e]indole-7-carboxylate (7). A solution of 18 (32.5 mg, 0.022 mmol) in dry THF–DMF (2.5:1, 1.0 mL) was treated with 10% palladium on carbon (16.3 mg, 0.5 wt equiv) and placed under an atmosphere of H₂ (1 atm) at 23 °C (24 h). The reaction mixture was filtered through Celite, and the solvent was removed in vacuo. Chromatography (5 mm × 6 cm, 100% EtOAc–100% THF gradient elution) gave 7 (8.3 mg, 20.6 mg theoretical, 40%) as a dark green solid: mp > 275 °C dec (green flakes, THF); ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.59 (br s, 1 H, NH), 11.33 (br s, 1 H, NH), 11.25 (br s, 1 H, NH), 11.21 (br s, 1 H, NH), 7.63 (s, 1 H, C4-H), 7.61 (s, 1 H, C4'-H), 7.60 (s, 1 H, C4''-H), 7.51 (s, 1 H, C4'''-H), 7.01 (s, 1 H, C8''-H or C8'''-H), 6.98 (s, 1 H, C8'-H or C8'''-H), 6.85 (br s, 2 H, C8-H and C8'-H), 5.60–5.40 (m, 8 H, NH₂), 4.65–4.50 (m, 4 H, C2-H₂ and C2'-H₂), 4.12 (t, 2 H, *J* = 8.1 Hz, C2''-H₂), 3.95 (t, 2 H, *J* = 8.1 Hz, C2'''-H₂), 3.89 (s, 3 H, CO₂CH₃), 3.30–3.05 (m, 8 H, C1-H₂, C1'-H₂, C1''-H₂, and C1'''-H₂), 1.50 (s, 9 H, *t*Bu); IR (KBr) ν_{\max} 3432, 2924, 1702, 1618, 1524, 1422, 1256, 1138, 1024, 762 cm⁻¹; FABMS (*m*-nitrobenzyl alcohol) *m/e* 928 (M⁺); FABHRMS (*m*-nitrobenzyl alcohol) *m/e* 929.4078 (C₅₀H₄₈N₁₂O₇ + H⁺ requires 929.3846).

Methyl 5-(Trimethylammonio)-3-(*tert*-butyloxycarbonyl)-1,2-dihydro-3H-pyrrolo[3,2-e]indole-7-carboxylate Iodide (8). A solution of ACDPI₁ (4, 50 mg, 0.15 mmol) in dry DMF (0.5 mL) was treated with NaHCO₃ (63 mg, 0.76 mmol, 5 equiv) and CH₃I (50 μ L, 0.76 mmol, 5 equiv) and stirred vigorously at 23 °C (12 h). Additional CH₃I (50 μ L, 0.76 mmol, 5 equiv) was added, and the mixture was stirred for 12 h (23 °C). The DMF was removed in vacuo, the resulting crude solid was slurried in water (2 × 3 mL), and the product was collected by centrifugation. Recrystallization from CH₃CN provided the TACDPI₁ (8, 61 mg, 75 mg theoretical, 81%) as a pale white plates: mp 160–161.5 °C dec (pale white plates, CH₃CN); ¹H NMR (CD₃CN, 300 MHz) δ 8.40 (br s, 1 H, NH), 7.93 (br s, 1 H, C4-H), 7.23 (s, 1 H, C8-H), 4.11 (t, 2 H, *J* = 8.7 Hz, NCH₂CH₂), 3.94 (s, 3 H, CO₂CH₃), 3.78 (s, 9 H, N(CH₃)₃), 3.32 (t, 2 H, *J* = 8.7 Hz, NCH₂CH₂), 1.55 (br s, 9 H, *t*Bu); IR (KBr) ν_{\max} 3432, 3008, 2966, 1698, 1636, 1522 cm⁻¹; EIMS *m/e* (relative intensity) 373 (M⁺ – I, 28), 317 (90), 273 (34), 57 (base); CIMS (isobutane) *m/e* 374 (M⁺ + H – I, base); EIHRMS *m/e* 373.1998 (C₂₀H₂₈N₃O₄ – I requires 373.2002).

Methyl 5-(Trimethylammonio)-3-[[5'-(trimethylammonio)-3'-(*tert*-butyloxycarbonyl)-1',2'-dihydro-3'H-pyrrolo[3',2'-e]indol-7'-yl]carbonyl]-1,2-dihydro-3H-pyrrolo[3,2-e]indole-7-carboxylate Diiodide (9). A solution of ACDPI₂ (5, 32.5 mg, 0.061 mmol) in dry DMF (0.6 mL) was treated with NaHCO₃ (102 mg, 1.23 mmol, 20 equiv) and CH₃I (60 μ L, 0.92 mmol, 15 equiv) and stirred vigorously at 23 °C (32 h). The solvent was removed in vacuo, the crude residue was washed with H₂O (4 × 2.5 mL), and the product was collected by centrifugation. Crystallization from CH₃OH–Et₂O provided the TACDPI₂ (9, 15 mg, 53 mg theoretical, 28%) as a pale yellow solid. Additional material could be obtained from the mother

liquors by repeated recrystallization: mp 150–152 °C dec (fine pale yellow needles, MeOH–Et₂O); ¹H NMR (CD₃CN, 300 MHz) δ 10.42 (br s, 2 H, NH), 8.87 (br s, 1 H, C4-H), 8.38 (br s, 1 H, C4'-H), 7.38 (s, 1 H, C8'-H), 7.22 (s, 1 H, C8-H), 4.70 (t, 2 H, *J* = 8.2 Hz, C2-H₂), 4.14 (t, 2 H, *J* = 8.2 Hz, C2'-H₂), 3.94 (s, 3 H, CO₂CH₃), 3.77 (s, 9 H, N(CH₃)₃), 3.75 (s, 9 H, N(CH₃)₃), 3.56 (t, 2 H, *J* = 8.2 Hz, C1-H₂), 3.37 (t, 2 H, *J* = 8.2 Hz, C1'-H₂), 1.55 (br s, 9 H, *t*Bu); IR (KBr) ν_{\max} 3424, 1686, 1624, 1516 cm⁻¹; FABMS (*m*-nitrobenzyl alcohol) *m/e* (relative intensity) 743 (M⁺ – I, 6), 154 (base); FABHRMS (*m*-nitrobenzyl alcohol) *m/e* 743.2402 (C₃₄H₄₄I₂N₆O₅ – I requires 743.2418).

Methyl 5-(Trimethylammonio)-3-[[5'-(trimethylammonio)-3'-(*tert*-butyloxycarbonyl)-1',2'-dihydro-3'H-pyrrolo[3',2'-e]indol-7'-yl]carbonyl]-1,2'-dihydro-3'H-pyrrolo[3',2'-e]indol-7'-yl]carbonyl]-1,2-dihydro-3H-pyrrolo[3,2-e]indole-7-carboxylate Tris(methanesulfonate) (10). A solution of ACDPI₃ (6, 24.9 mg, 0.034 mmol) and NaHCO₃ (57 mg, 0.68 mmol, 20 equiv) in dry DMF (0.3 mL) was treated with Me₂SO₄ (47 μ L, 0.51 mmol, 15 equiv), and the resulting reaction mixture was stirred vigorously at 23 °C (48 h). The solvent was removed in vacuo, the crude residue was washed with H₂O (2 × 2.5 mL), and the dark green solid was collected by centrifugation. Recrystallization from CH₃OH provided the TACDPI₃ (10, 10.7 mg, 38 mg theoretical, 28%) as dark green flakes. Additional product could be obtained by recrystallization of the residue derived from the mother liquors: mp > 240 °C dec (dark green flakes, MeOH); ¹H NMR (DMSO-*d*₆, 300 MHz) δ 12.44 (br s, 2 H, two NH), 12.13 (br s, 1 H, NH), 8.89 (br s, 1 H, C4-H), 8.72 (s, 1 H, C4'-H), 8.17 (br s, 1 H, C4''-H), 7.49 (s, 2 H, C8''-H and C8'-H), 7.38 (s, 1 H, C8-H), 4.70 (t, 4 H, *J* = 8.3 Hz, C2-H₂ and C2'-H₂), 4.30 (t, 2 H, *J* = 8.3 Hz, C2''-H₂), 3.94 (s, 3 H, CO₂CH₃), 3.82 (s, 18 H, N(CH₃)₃), 3.78 (s, 9 H, N(CH₃)₃), 3.60 (t, 4 H, *J* = 8.3 Hz, C1-H₂ and C1'-H₂), 2.46 (t, 2 H, *J* = 8.3 Hz, C1''-H₂, partially obscured by H₂O peak), 2.54 (s, 9 H, MeSO₄), 1.52 (br s, 9 H, *t*Bu); IR (KBr) ν_{\max} 3468, 2958, 2122, 1720, 1638, 1510 cm⁻¹; FABMS (DDT/DTE) *m/e* (relative intensity) 1214 (M⁺ + Na), 1080 (M⁺ – MeSO₄); FABHRMS (DDT/DTE) *m/e* 1080.4150 (C₅₀H₄₆O₁₄N₉S₂ requires 1080.4171).

DNA Binding Studies.²⁴ DNA (0.887 × 10⁻⁵ M) was mixed with ethidium bromide (0.444 × 10⁻⁵ M) in a 2:1 ratio of base-pair:ethidium in a 0.1 M Tris–HCl, 0.1 M NaCl, pH 8.0 buffer solution. The fluorescence spectrophotometer was calibrated at 23 °C to 100% F and 0% F with the DNA–ethidium buffer solution and ethidium buffer solution, respectively. The premixed DNA–ethidium solution was titrated dropwise with the agents (e.g., 0.2 mM CDPI₃ in DMSO, generally 0.2–0.8 mM) and incubated at 23 °C for approximately 30 min prior to each fluorescence reading. The fluorescence measurements were conducted at 545-nm excitation and 595-nm emission wavelengths with a slit opening of 20 nm. Under these conditions, ACDPI_n and TACDPI_n, alone or in the presence of DNA did not interfere with the fluorescence measurements. The relative and absolute binding constants were determined at 50% ethidium bromide displacement as measured by a drop in fluorescence to 50%. The binding constants of ethidium bromide employed to calculate the absolute binding constants with a competitive binding model²² were 6.5 × 10⁵ M⁻¹, poly[dA]–poly[dT]; 4.5 × 10⁶ M⁻¹, poly[dG]–poly[dC]; and 9.5 × 10⁶ M⁻¹, poly[d(A-T)]–poly[d(A-T)].²⁵

Abbreviations. CPI, 7-methyl-1,2,8,8a-tetrahydrocyclopropa[1,2-c]pyrrolo[3,2-e]indol-4(5H)-one; CDPI, methyl N³-carbamoyl-1,2-dihydro-3H-pyrrolo[3,2-e]indole-7-carboxylate; ACDPI, 5-amino-CDPI; TACDPI, 5-(trimethylammonio)-CDPI.

Acknowledgment. This work was supported by the National Institutes of Health (CA 41986).

Supplementary Material Available: ¹H NMR of 5–10, 15–16, and 18 (9 pages). Ordering information is given on any current masthead page.

(24) Fluorescence measurements used in the DNA binding studies were obtained on a Perkin-Elmer MPF-44A Fluorescence Spectrophotometer. The DNA used in the binding studies was purchased from Sigma.

(25) Baguley, B. C.; Falkenau, E.-M. *Nucl. Acids Res.* 1978, 5, 161.